US FDA approves Axsome's drug for Alzheimer's-related agitation - Reuters
US FDA approves Axsome's drug for Alzheimer's-related agitation Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWVphYlZWc0RER3F3c09sMXhsQkE4b0lzaXhWM3FYV2lza19mU3Y1WWI4WElZbmxOc3FGUE9UaUN2VmVQYjRuaHJQU0lQS3V5Y2Z5Wk1lVkNGelEyMHMwSXR1YWRWYk9ULV9zTFBvX291RmpHakpodm04MHpfWl9lZlVhVGdiM2tiQ3BWb080NWFrR1VUdUxsb2FmTE5LT2xnSlZrVHotRzY3OHV0d0d2djlUSUVEV3lQeXY5VnBvWWlHUTZZNXd1Yw?oc=5" target="_blank">US FDA approves Axsome's drug for Alzheimer's-related agitation</a> <font color="#6f6f6f">Reuters</font>
The FDA approved Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) for treating agitation in Alzheimer's patients, marking the first non-antipsychotic treatment for this condition.
Axsome Therapeutics announced the FDA approval of Auvelity for treating agitation associated with Alzheimer's disease, a first-in-class treatment targeting NMDA and sigma-1 receptors.
The FDA approved Axsome Therapeutics' drug, Auvelity, to treat agitation in Alzheimer's patients, offering an alternative to antipsychotic drugs.
Axsome Therapeutics received FDA approval for Auvelity to treat Alzheimer's disease agitation, accessing a $1 billion-plus market and offering a clean label compared to competitors.
The FDA approved Axsome Therapeutics' Auvelity for treating agitation in Alzheimer's disease, providing a new option to ease caregiver burden.
Similar Stories
Related coverage based on topic and tags
US FDA approves Regeneron's rare bone disorder drug - Reuters
US FDA approves Regeneron's rare bone disorder drug Reuters
August 19, 2026 at 06:53 PMPrader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Reuters
August 12, 2026 at 04:25 PMUS FDA approves Bristol Myers' blood cancer treatment - Reuters
US FDA approves Bristol Myers' blood cancer treatment Reuters
August 13, 2026 at 09:33 PMEyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters
August 17, 2026 at 03:45 PMCapricor shares skyrocket as FDA agrees to review new Duchenne drug data - Reuters
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data Reuters
August 14, 2026 at 10:41 AMNovartis defeats UK court bid to invalidate blockbuster drug Entresto patent - Reuters
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent Reuters
August 13, 2026 at 09:31 PM